HM1 Leadership Restructure

The Board has announced the restructure of its leadership, transitioning from a full-time CEO role to a more streamlined model. As a result, Brett Jollie will step down as CEO and Richard Howes will be appointed to a new part-time role of Managing Director.

HM1 Leadership Restructure

May 19, 2025
The Board has announced the restructure of its leadership, transitioning from a full-time CEO role to a more streamlined model. As a result, Brett Jollie will step down as CEO and Richard Howes will be appointed to a new part-time role of Managing Director.
Read Transcript

Hearts & Minds Restructure and Appointment of Richard Howes as Managing Director

The Board of Hearts and Minds Investments Limited (“HM1”; “Hearts & Minds”) has announced the restructure of its leadership, transitioning from a full-time CEO role to a more streamlined model. As a result, Brett Jollie will step down as CEO and Richard Howes will be appointed to a new part-time role of Managing Director.

Richard is a globally experienced executive and director with over 30 years’ experience in the financial services industry. His most recent executive role was as Group CEO of Challenger Limited, an ASX-listed asset manager and retirement income provider.  

Richard Howes will join HM1’s Board and executive team as its Managing Director on 1 June 2025 as well as joining the Investment Committee and Conference Fund Manager Selection Committee.

Since joining HM1 in December 2024, Brett has undertaken a comprehensive review of the business, identifying key opportunities to enhance HM1’s operations and strategic focus.

Under Brett’s leadership, HM1 has:

  • Conducted a thorough review of its operating model
  • Established a new dedicated investment operations function to improve operational efficiency and expertise
  • Implemented an investment management system to automate and improve portfolio management and oversight

These enhancements have significantly improved automation and efficiency and, together with the broader capability in the senior HM1 team, have given the Board the opportunity to evolve its leadership structure, replacing the full-time CEO role with a part-time Managing Director.  

Brett will remain with HM1 until 30 June 2025 to oversee a smooth transition.

Chris Cuffe, Chair of HM1, commented:

On behalf of the Board, I want to sincerely thank Brett for his leadership and the significant contributions he has made in such a short time. His efforts have strengthened HM1, identifying key enhancements that will result in a more efficient, streamlined business with reduced operational risk. Ironically, it is because of these improvements that we are now able to transition to a leaner leadership structure. We greatly appreciate Brett’s impact.

We are delighted to be welcoming Richard to the team. Over his 30-year financial services career, he has successfully managed and grown multi-billion dollar investment portfolios and investment product businesses. I am confident that Richard will help us continue to improve our investment offering and to grow our impact.

The Board will be working closely with Brett and Richard to ensure a smooth transition of leadership.

Brett commented:

I am grateful to the Board for the opportunity to lead HM1 and to contribute to its unique mission. In a short time, we’ve made significant progress in strengthening the business, streamlining operations, and positioning HM1 for the future. I’m confident that these enhancements will support the company’s long-term success and purpose. I want to thank the Board and the HM1 team for their support and collaboration, and I wish them the very best as they continue to add value to shareholders and provide meaningful support to medical research.

Richard commented:

I am honored to be given the responsibility to be the Managing Director of Hearts & Minds which represents both an extraordinary philanthropic success story and a genuine innovation in terms of its investment proposition and process. I am excited to have the opportunity to work with HM1’s outstanding Board and management team to build on this success and to further innovate.

Hearts & Minds Restructure and Appointment of Richard Howes as Managing Director

The Board of Hearts and Minds Investments Limited (“HM1”; “Hearts & Minds”) has announced the restructure of its leadership, transitioning from a full-time CEO role to a more streamlined model. As a result, Brett Jollie will step down as CEO and Richard Howes will be appointed to a new part-time role of Managing Director.

Richard is a globally experienced executive and director with over 30 years’ experience in the financial services industry. His most recent executive role was as Group CEO of Challenger Limited, an ASX-listed asset manager and retirement income provider.  

Richard Howes will join HM1’s Board and executive team as its Managing Director on 1 June 2025 as well as joining the Investment Committee and Conference Fund Manager Selection Committee.

Since joining HM1 in December 2024, Brett has undertaken a comprehensive review of the business, identifying key opportunities to enhance HM1’s operations and strategic focus.

Under Brett’s leadership, HM1 has:

  • Conducted a thorough review of its operating model
  • Established a new dedicated investment operations function to improve operational efficiency and expertise
  • Implemented an investment management system to automate and improve portfolio management and oversight

These enhancements have significantly improved automation and efficiency and, together with the broader capability in the senior HM1 team, have given the Board the opportunity to evolve its leadership structure, replacing the full-time CEO role with a part-time Managing Director.  

Brett will remain with HM1 until 30 June 2025 to oversee a smooth transition.

Chris Cuffe, Chair of HM1, commented:

On behalf of the Board, I want to sincerely thank Brett for his leadership and the significant contributions he has made in such a short time. His efforts have strengthened HM1, identifying key enhancements that will result in a more efficient, streamlined business with reduced operational risk. Ironically, it is because of these improvements that we are now able to transition to a leaner leadership structure. We greatly appreciate Brett’s impact.

We are delighted to be welcoming Richard to the team. Over his 30-year financial services career, he has successfully managed and grown multi-billion dollar investment portfolios and investment product businesses. I am confident that Richard will help us continue to improve our investment offering and to grow our impact.

The Board will be working closely with Brett and Richard to ensure a smooth transition of leadership.

Brett commented:

I am grateful to the Board for the opportunity to lead HM1 and to contribute to its unique mission. In a short time, we’ve made significant progress in strengthening the business, streamlining operations, and positioning HM1 for the future. I’m confident that these enhancements will support the company’s long-term success and purpose. I want to thank the Board and the HM1 team for their support and collaboration, and I wish them the very best as they continue to add value to shareholders and provide meaningful support to medical research.

Richard commented:

I am honored to be given the responsibility to be the Managing Director of Hearts & Minds which represents both an extraordinary philanthropic success story and a genuine innovation in terms of its investment proposition and process. I am excited to have the opportunity to work with HM1’s outstanding Board and management team to build on this success and to further innovate.

Disclaimer: This material has been prepared by Hearts & Minds Investments, published on May 19, 2025. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
June 12, 2025

Coeur Mining – a high-conviction precious metals re-rating story

Coeur Mining provides access to precious metals production in politically stable jurisdictions, with potential for operational and valuation upside.

Read More
March 10, 2025

Reporting Season Insights: HM1 Core Portfolio Holdings

We spoke to our dedicated fund managers for an update on some of our major portfolio holdings following reporting season.

Read More
February 20, 2025

Significant increase in profit and increased fully franked dividend

We're pleased to declare an increased half-year fully franked dividend of 8.0 cents per share payable in April 2025.

Read More
December 10, 2024

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
impact-podcasts
December 5, 2024

HM1 CEO Succession

Hearts and Minds Investments Limited advises that Paul Rayson intends to retire from the position of Chief Executive Officer, effective 19 February 2025.

Read More
Chris Cuffe, chairman of Hearts and Minds Investments, with chief investment officer Charlie Lanchester. Picture: John FederChris Cuffe, chairman of Hearts and Minds Investments, with chief investment officer Charlie Lanchester. Picture: John FederChris Cuffe, chairman of Hearts and Minds Investments, with chief investment officer Charlie Lanchester. Picture: John FederChris Cuffe, chairman of Hearts and Minds Investments, with chief investment officer Charlie Lanchester. Picture: John Feder
November 14, 2024

Sohn Hearts & Minds Investments fund targets $1.5bn valuation

‍Hearts & Minds Investments chair Chris Cuffe is hoping for HM1 to grow to more than $1.5bn in the next five years.

Read More
September 24, 2024

Asian Market Potential with Tom Naughton of Prusik

CIO Charlie Lancaster sits down with Tom Naughton, CIO of Prusik Investment Mgmt. Tom shares his investment philosophy, the opportunities and challenges in Asian markets, and how his 2023 conference stock pick, Swire Pacific (0019.HK), delivered an impressive 30% return.

Read More
investing
September 6, 2024

Exploring HM1 Top Stocks: Key Insights from Reporting Season

We have just come to the end of reporting season and the fund managers of our major portfolio holdings gave us their insights into the latest results of our key holdings.

Read More
September 4, 2024

Building Hearts and Minds with Co-Founders Matthew Grounds and Guy Fowler

In this episode, co-founders Matthew Grounds AM and Guy Fowler OAM discuss their journey in building Hearts & Minds and its philanthropic model that has donated over $70 million to medical research.

Read More
investing
June 25, 2024

Navigating the Resource Sector with Jeremy Bond of Terra Capital

In this episode, we chat with Jeremy Bond, Founder of Terra Capital and HM1 Conference Fund Manager. Tune in for insights into the world of resource investments and the exciting opportunities that lie ahead.

Read More
investing
June 11, 2024

Prof. Nadia Badawi on Cerebral Palsy Breakthroughs and Neonatal Care

Dive deep into the groundbreaking work of Professor Nadia Badawi, an internationally recognised neonatologist and expert in Cerebral Palsy.

Read More
impact-podcasts
May 28, 2024

Investment Insights: Rikki Bannan on Top Picks and Trends

Join us for an engaging episode featuring Rikki Bannan, Portfolio Manager of IFM Investors and HM1 Conference Fund Manager. This episode explores Rikki's career journey, investment strategies, and her 2023 conference stock pick, Telix Pharmaceuticals (ASX.TLX).

Read More
investing
March 7, 2024

Exploring HM1 Stocks: Key Insights from Reporting Season

We asked our fund managers for an update on how some of our key positions are performing off the back of the reporting season. Overall, it was a good period for the fund with some good moves to the upside.

Read More
February 6, 2024

Stock Story: ResMed

This month we take a deep dive into ResMed - one of the conference stocks within the fund that was astutely picked by Chris Kourtis of Ellerston Capital.

Read More
Ms Lorraine Berends. Director Qantas Super Fund, Pinnacle Investment Management Received an AM in the 2024 Australia Day Honours.Ms Lorraine Berends. Director Qantas Super Fund, Pinnacle Investment Management Received an AM in the 2024 Australia Day Honours.Ms Lorraine Berends. Director Qantas Super Fund, Pinnacle Investment Management Received an AM in the 2024 Australia Day Honours.Ms Lorraine Berends. Director Qantas Super Fund, Pinnacle Investment Management Received an AM in the 2024 Australia Day Honours.
January 25, 2024

Australia Day Honours: Lorraine Berends of Qantas Super

Congratulations to our Board of Director, Lorraine Berends, who was awarded AM in the Australia Day honours.

Read More
December 10, 2024

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
impact-podcasts
September 24, 2024

Asian Market Potential with Tom Naughton of Prusik

CIO Charlie Lancaster sits down with Tom Naughton, CIO of Prusik Investment Mgmt. Tom shares his investment philosophy, the opportunities and challenges in Asian markets, and how his 2023 conference stock pick, Swire Pacific (0019.HK), delivered an impressive 30% return.

Read More
investing
September 4, 2024

Building Hearts and Minds with Co-Founders Matthew Grounds and Guy Fowler

In this episode, co-founders Matthew Grounds AM and Guy Fowler OAM discuss their journey in building Hearts & Minds and its philanthropic model that has donated over $70 million to medical research.

Read More
investing
June 25, 2024

Navigating the Resource Sector with Jeremy Bond of Terra Capital

In this episode, we chat with Jeremy Bond, Founder of Terra Capital and HM1 Conference Fund Manager. Tune in for insights into the world of resource investments and the exciting opportunities that lie ahead.

Read More
investing
June 11, 2024

Prof. Nadia Badawi on Cerebral Palsy Breakthroughs and Neonatal Care

Dive deep into the groundbreaking work of Professor Nadia Badawi, an internationally recognised neonatologist and expert in Cerebral Palsy.

Read More
impact-podcasts
May 28, 2024

Investment Insights: Rikki Bannan on Top Picks and Trends

Join us for an engaging episode featuring Rikki Bannan, Portfolio Manager of IFM Investors and HM1 Conference Fund Manager. This episode explores Rikki's career journey, investment strategies, and her 2023 conference stock pick, Telix Pharmaceuticals (ASX.TLX).

Read More
investing
December 6, 2023

Peter Cooper talks building and instilling a culture of humility and excellence

In this episode, our guest is the renowned investor, Peter Cooper, founder and Chief Investment Officer of Cooper Investors (Core Fund Manager). A founding supporter of Hearts and Minds, Peter is a staunch advocate of our model and its philanthropic purpose, actively engaging in every facet of Hearts and Minds.

Read More
investing
November 28, 2023

Jun Bei Liu on her high conviction investment strategy

In this episode, HM1 Chief Investment Officer Charlie Lanchester is joined by Jun Bei Liu. Jun Bei is the Portfolio Manager of Tribeca’s Alpha Plus Fund and since taking over managing the Fund, she has quadrupled AUM.

Read More
investing
November 21, 2023

The world of rare genetic disease research

In this episode, we speak to Associate Professor Gina Ravenscroft. Gina is an Associate Professor in Neurogenetics at the Harry Perkins Institute of Medical Research in Perth. Her research interests are in rare genetic diseases, with a particular focus on neurogenetic diseases in babies and children.

Read More
impact-podcasts
November 14, 2023

Learn what makes a high conviction investment and how to avoid short-term noise

In this episode, our Core Fund Manager Magellan shares how they select top stocks for the HM1 portfolio.

Read More
investing
November 7, 2023

Delve into the world of kids critical care and trauma research

In thie episode, we are joined by Dr. Marino Festa, or Rino for short. He is the Medical Director of NSW Kids ECMO Referral Service and a senior specialist in Paediatric Intensive Care at Children’s Hospital at Westmead.

Read More
impact-podcasts
October 31, 2023

Where Regal's Phil King is searching for opportunities

HM1's CIO, Charlie Lanchester, talks to Phil King of Regal Funds about his passion for stocks, his ongoing search for opportunities, and some of the sectors he’s excited by right now. Phil King of Regal Funds, has been a tremendous supporter of Hearts & Minds since the beginning.

Read More
investing
October 24, 2023

Preventing recurrent miscarriages and birth defects

In this episode, CEO Paul Rayson is joined by renowned biomedical researcher Professor Sally Dunwoodie. Prof. Dunwoodie's groundbreaking work has revolutionised clinical practices and enabled genetic diagnostic tests worldwide. In 2017, her team achieved a double breakthrough with the potential to prevent recurrent miscarriages and various birth defects.

Read More
impact-podcasts
October 17, 2023

Nick Griffin on how he finds global winners

In this episode, CIO Charlie Lanchester chats with Nick Griffin, the founding partner and CIO of Munro Partners, one of HM1's Core Fund Managers. They go over his career to date, reflect on the lessons he’s learned, and trace the decisions that led to him starting Munro.

Read More
investing
October 10, 2023

How A/Prof Matt Call is teaching our body to kill cancer

In this episode, CEO Paul Rayson is joined by WEHI’s Associate Professor Matt Call to talk about his incredible research. Matt’s team teaches and trains the body's own immune cells to target and kill cancer cells.

Read More
impact-podcasts

No results found.

Please try a different search keyword or filter.